DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Ivan Silva - 1 Heroe - 1 Lionel Messi - 1 Thea Mihu - 1 Ba Jia Jiang - 1 Surong Zhu - 1 Scott Galloway - 1 Leon Wang - 1
Top related locs:
Mexico Sweden Hanoi Vietnam Germany Fujian China Ohio
Top related orgs:
CNN — Organizers - 1 Italiana - 1 Diesel - 1

Search resuls for: "Leon Wang"


2 mentions found


☆ iPhone Photography Awards 2023: Winners unveiled
  + stars: | 2023-08-03 | by ( Christy Choi | ) edition.cnn.com   time to read: +2 min
CNN —Organizers announced the winners of the 2023 iPhone Photography Awards on Monday. Scott Galloway/iPhone Photography Awards"Palazzo della Civiltà Italiana,"Rome, Italy, by Leon Wang (United States) won 3rd place in Architecture. Sofia Ershova/iPhone Photography Awards"Duet," Zhejiang, China, by Zhang Xiaojun (China) won 3rd place in Children. Zhang Xiaojun/iPhone Photography Awards"Kapkungkap Tadau" Phuket, Thailand by Juan Castaneda (United States) won 2nd place in Series. Juan Castaneda/iPhone Photography Awards"Bi Mo," Zhaojue County, China, by Jian Wang (China) won 2nd place in People.
Persons: Ivan Silva, Heroe, Lionel Messi, Thea Mihu, Ba Jia Jiang, Surong Zhu, Scott Galloway, Leon Wang, Sofia Ershova, Zhang Xiaojun, Juan Castaneda, Jian Wang, Sasa Borozan, Beata Krowicka, Barry Mayes Organizations: CNN — Organizers, Italiana, Diesel Locations: Mexico, Sweden, Hanoi, Vietnam, Germany, Fujian, China, Ohio, USA, United States, Rome, Italy, Architecture, California, Zhejiang, Phuket, Thailand, Zhaojue County, People, Nature, Croatia, Bosnia, Herzegovina, Grande, Argentina, Poland, Travel, Sierra Leone, United Kingdom
☆ This biotech stock can jump more than 90%, Barclays says
  + stars: | 2022-12-08 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Little-known Insmed could take off as one of its drugs with conditional approval and another in development show promise, according to Barclays. Analyst Leon Wang initiated the stock as overweight with a price target of $37, which presents a 94.9% upside from Wednesday's close. The company focuses on pulmonology-focused commercial biotech, with two major medications for bronchiectasis, which is when airways in lungs are widened, and a lung disease. Assuming strong data out of the third trial, Wang said the medication could hit the market in 2025. He said Insmed will likely surpass sales guidance, which was already set for a 30% year-over-year increase, in 2022.
0 next >>
Total: 2